

# A worsened prognosis for patients after stroke with newly diagnosed atrial fibrillation compared to having a preexisting arrhythmia

Justyna Tracz<sup>1</sup>, Iwona Gorczyca-Głowacka<sup>2\*</sup>, Anita Rosołowska<sup>1</sup>, Ewa Kołodziejska<sup>3</sup>, Beata Woźakowska-Kapton<sup>2,4</sup>

<sup>1</sup>Clinic of Neurology, Swietokrzyskie Neurology Center, Kielce, Poland

<sup>2</sup>Faculty of Medical and Health Sciences, University of Jan Kochanowski, Kielce, Poland

<sup>3</sup>Department of Internal Diseases and Diabetology, Hospital St. Alexander, Kielce, Poland

<sup>4</sup>1<sup>st</sup> Clinic of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Center, Kielce, Poland

**Submitted:** 30 March 2022; **Accepted:** 25 July 2022

**Online publication:** 3 August 2022

Arch Med Sci 2025; 21 (3): 757–765

DOI: <https://doi.org/10.5114/aoms/152339>

Copyright © 2022 Termedia & Banach

**\*Corresponding author:**

Iwona Gorczyca-Głowacka  
MD, PhD

Faculty of Medical  
and Health Sciences

The University of Jan  
Kochanowski

IX Wieków Kielc 19 A

25-317 Kielce, Poland

E-mail: iwona.gorczyca@interia.pl

## Abstract

**Introduction:** Atrial fibrillation (AF) is a major cause of ischemic stroke. Patients with undiagnosed AF lack the stroke prevention provided by oral anti-coagulants. The aim of this study was to compare the in-hospital mortality rate between ischemic stroke patients diagnosed with AF *de novo* and ischemic stroke patients diagnosed with AF prior to hospitalization for stroke.

**Material and methods:** We identified patients admitted to the Neurology Center during the years 2013–2014 with acute ischemic stroke and AF. We analyzed in-hospital outcomes in patients with newly diagnosed AF and those with known AF. The study endpoint was death during hospitalization.

**Results:** The study included 2,000 patients with acute ischemic stroke, out of whom 579 (29%) patients were diagnosed with AF. AF was newly diagnosed in 123 (21.2%) patients (new-AF group), while 456 (78.8%) patients had a history of AF (previous-AF group). The mean National Institutes of Health Stroke Scale (NIHSS) score at admission was 7.2 points in the new-AF group and 3.7 in the previous-AF group ( $p < 0.001$ ). In-hospital death was more common in the new-AF group (13 patients, 10.6%) than in the previous-AF group (16 patients, 3.5%) ( $p = 0.003$ ). In multivariate analysis, the NIHSS score at admission in the new-AF group was associated with higher mortality, while in the previous-AF group, the NIHSS score at admission and multiple ischemic foci were risk factors of in-hospital mortality.

**Conclusions:** Newly diagnosed AF in ischemic stroke patients significantly worsens prognosis compared to patients previously diagnosed with AF. Early detection of latent AF and subsequent use of anticoagulation are important in preventing severe stroke.

**Key words:** atrial fibrillation, ischemic stroke, mortality, CHA<sub>2</sub>DS<sub>2</sub>-VASc scale.

## Introduction

Atrial fibrillation (AF) is one of the most common supraventricular arrhythmias, affecting 1.0–1.5% of the world population [1]. The most serious complication of AF is a thromboembolic event such as stroke,

transient ischemic attack (TIA), or systemic arterial embolism [2]. Atrial fibrillation contributes to thromboembolism by way of various mechanisms. The most significant series of mechanical events leading to thromboembolism begins when the left atrium of the heart becomes congested with blood. This cardiac congestion leads to diminished functionality, which can trigger the formation of a thrombus created from the congested material. Once formed, arrhythmic events can loosen the thrombus and carry it into the bloodstream, where it can become lodged in a blood vessel, causing a blockage of blood flow, leading to a stroke [3, 4]. The presence of AF is associated with a 5-fold increase in the incidence of ischemic stroke in patients with AF [5–7]. Effective prophylaxis with anticoagulants is an important factor in preventing stroke in patients with AF [6–8]. It is estimated that the annual stroke incidence in AF patients not receiving anticoagulation therapy accounts for 4.9–5.7% of cases [9, 10]. Undiagnosed AF may cause up to 30% of all cardiogenic strokes [6, 8]. In AF patients with stroke, the prognosis is worse compared to patients with a sinus rhythm, with in-hospital mortality rates as high as 30% [6, 11–13]. The risk of annual mortality and disability after stroke in patients with AF is two times higher than in the population without AF [7].

The aim of the study was to compare in-hospital mortality between ischemic stroke patients diagnosed with AF *de novo* (during hospitalization due to stroke) and ischemic stroke patients diagnosed with AF prior to hospitalization due to stroke.

## Material and methods

### Study group

A retrospective analysis was conducted on acute stroke patients hospitalized in a tertiary center during the years 2013 and 2014. Patients with cerebral hemorrhage and TIA were not included in this study.

Stroke was diagnosed by clinical presentation as an episode of neurological dysfunction lasting more than 24 h and imaging studies (head computed tomography or magnetic resonance imaging).

Two groups of study patients were identified, using criteria established by the European Society of Cardiology (ESC): 1) new-AF group: these patients had no previous history of arrhythmia but AF was diagnosed *de novo*, concurrently, during their hospital stay for stroke; 2) previous-AF group: these patients had been diagnosed with AF before hospitalization for stroke.

In addition to ESC diagnostic guidelines, AF diagnoses were based on an electrocardiogram showing irregular atrial rhythm lasting 30 s or longer [14].

We compared baseline characteristics and outcomes between these two groups.

The study was approved by the ethics committee. All procedures performed in studies involving human participants were in accordance with the ethical standards of the local ethics committee and with the Declaration of Helsinki (1964) and its later amendments or comparable ethical standards.

### Analyzed data

The following data was analyzed: demographic data (age, sex), comorbidities, diagnostic study results, and hospital course. Risk factors for stroke, such as hypertension, diabetes mellitus, heart disease, and current smoking were assessed.

Hypertension was defined as systolic blood pressure  $\geq 140$  mm Hg or diastolic blood pressure  $\geq 90$  mm Hg in repeated tests, any use of antihypertensive drugs or self-reported history.

Diabetes mellitus was defined as a fasting blood glucose level greater than 126 mg/dl after a minimum of two tests or a glucose level greater than 200 mg/dl any time during the day, self-reported patient history or use of anti-diabetic medications [8]. Heart disease was determined by a previous history of coronary artery disease or heart failure.

The extent of ischemia was evaluated by head computed tomography or magnetic resonance imaging. Head imaging was performed at admission and repeated during hospitalization.

Hemorrhagic transformation was defined as a focus of hemorrhage on brain CT or MRI.

Doppler ultrasound was used to evaluate extracranial cerebral circulation.

In all patients, resting 12-lead electrocardiography was performed at admission and discharge.

In most patients ( $n = 1489$ ), Holter monitoring was conducted for 24 h following admission.

Also, transthoracic echocardiography was conducted on selected patients ( $n = 1230$ ).

Stroke severity was evaluated in accordance with the National Institutes of Health Stroke Scale (NIHSS) at admission. For the assessment of stroke risk in AF patients, the CHADS<sub>2</sub> scale was applied accounting for previous history of stroke, transient ischemic attack, systemic thromboembolism, age  $\geq 75$ , hypertension, diabetes, and heart failure, together with the CHA<sub>2</sub>DS<sub>2</sub>VASc scale with additional points for female sex, age 65–74 and vascular disease. A score of 0 on both scales denotes low risk, 1 point intermediate risk, and  $\geq 2$  points high risk of thromboembolic events. Evaluation using both CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>VASc scales was conducted twice, without considering the current stroke event (pre-stroke CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>VASc) as well as taking into account the

current episode (post-stroke CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc).

### Statistical analysis

Categorical data were presented as the number of patients and for the ordinal data means with SD were used. To determine differences between the groups the  $\chi^2$  test was applied for categorical data (with the exception of cases of occurrence numbers less than 5 in contingency tables where Fisher's exact test was performed) and Student's *t*-test was used for verification of hypothesis of equality of the means for continuous data. Statistical significance was considered for *p*-values lower than 0.05 calculated for two-tailed tests. Odds ratio parameters with 95% confidence intervals and corresponding *p*-values were calculated, separately for both groups, using a logistic regression model to assess the influence of the predictors on death during hospitalization. A univariate analysis was followed by multivariate analysis performed for a selected subset of variables considered as the most important, including the ones found to be statistically significant in the univariate model for both groups. Statistical analyses were performed using R: A language and environment for statistical computing, R Development Core Team (2017), <http://www.R-project.org/>. For the cases of zero cells the model was run using the Bayesian framework (namely the "bayesglm" function from the "arm" package), which was considered to be more appropriate and leading to less extreme estimates. However, there were no differences in terms of statistical significance between the Bayesian and the standard ("glm" function) approach.

## Results

### Baseline characteristics

Of the entire study population of 2,000 ischemic stroke patients, AF was diagnosed in 579 (29%), who were subject to further study. Of these AF patients, the mean age was 78.6 years and the majority were over 74 (408 patients, 70.4%). This group included 358 (61.8%) females.

Within the group of 579 patients with AF, arrhythmia was newly diagnosed in 123 (21.2%) individuals (new-AF group), while 456 patients (78.8%) had a previous history of AF (previous-AF group) (Figure 1). The new-AF group included 77 females (66.6%), while the previous-AF group included 281 females (61.2%, *p* = 0.93).

Among patients with stroke and AF (*n* = 579), the most common coexisting pathologies were hypertension (471; 81.3%), coronary artery disease (278; 48%), heart failure (167; 28.8%) and diabetes (160; 27.6%). Table I shows clinical characteristics of new-AF and previous-AF groups.

The pre-hospital stroke risk expressed by the CHA<sub>2</sub>DS<sub>2</sub>-VASc score was, on average, higher in the previous-AF group than in the new-AF group (5.1 vs. 4.6, *p* = 0.001). In the previous-AF group, high stroke risk rate expressed by a high pre-stroke CHA<sub>2</sub>DS<sub>2</sub>-VASc score was higher than in the new-AF group. The difference was statistically significant for patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score > 5 points (Table II).

Figure 2 shows pre-stroke CHA<sub>2</sub>DS<sub>2</sub>-VASc scores for the entire study group.

Stroke severity, determined by the mean NIHSS score, was higher in the group with new AF than in the group with previous AF (7.2 vs. 3.7, *p* < 0.001).

In the new-AF group, 14 (11.4%) patients received antiplatelet therapy before hospitalization, but there were no patients who received oral anticoagulation, whereas in the previous-AF group, 83 (18.2%) patients received anticoagulants (all patients were treated with vitamin K antagonists), 78 (17.1%) patients received antiplatelet agents, and 21 (4.6%) patients did not receive any stroke prophylaxis.

Within the combined study population, thrombolysis was used in 44 patients (7.6%): 15 (12.2%) from the new-AF group and 29 (6.4%) from the previous-AF group (*p* < 0.048). In the study group thrombectomy was not used. Hemorrhagic transformation during hospitalization was observed in 5 patients (4.1%) from the new-AF group and in 13 (2.9%) from the previous-AF group (*p* = 0.692).

The endpoint of an in-hospital death was more common in the new-AF group (13 patients; 10.6%) than in the previous-AF group (16 patients; 3.5%) (*p* = 0.003).

### Univariate analyses of predictors of death at hospitalization in the new-AF group and the previous-AF group

In univariate analyses, the risk factors of death were identified and compared between groups. In the new-AF group, the NIHSS score at admis-




Figure 1. Flow chart of the study

**Table I.** Clinical characteristics of the study group

Characteristic	All patients with AF n = 579	New-AF group n = 123	Previous-AF group n = 456	P-value
Females, n (%)	358 (61.8)	77 (66.6)	281 (61.2)	0.93
Age [years]	78.6 (41.7)	79.4 (31.1)	78.4 (39.6)	0.27
Age < 50 years, n (%)	1 (0.1)	0	1 (0.8)	0.99
Age 50–64 years, n (%)	55 (9.5)	11 (9)	44 (9.6)	
Age 65–74 years, n (%)	115 (19.9)	24 (19.5)	91 (19.6)	
Age > 74 years, n (%)	408 (70.5)	88 (71.5)	320 (70)	
Medical history, n (%):				
Hypertension	471 (81.3)	90 (73.2)	381 (83.6)	0.01
Heart failure	167 (28.8)	20 (16.3)	147 (32.2)	0.001
Diabetes mellitus	160 (27.6)	30 (24.4)	130 (28.5)	0.43
Previous thromboembolism	133 (23)	14 (11.4)	119 (26.1)	0.001
Previous stroke	112 (19.3)	12 (9.8)	100 (21.9)	0.004
Previous TIA	21 (3.6)	2 (1.6)	19 (4.2)	0.28
Coronary artery disease	278 (48)	44 (35.8)	234 (51.3)	0.003
Myocardial infarction	81 (14)	13 (10.6)	68 (14.9)	0.28
Percutaneous coronary intervention	31 (5.4)	3 (2.4)	29 (6.4)	0.12
Coronary artery bypass grafting	12 (2.1)	0	12 (2.6)	0.08
Atherosclerosis of the lower limbs	30 (5.2)	5 (4.1)	25 (5.5)	0.69
Chronic obstructive pulmonary disease	48 (8.3)	6 (4.9)	42 (9.2)	0.17
Hyperthyroidism	18 (3.1)	2 (1.6)	16 (3.5)	0.39
Hypothyroidism	30 (5.2)	4 (3.2)	26 (5.7)	0.36
Smoking	56 (9.7)	10 (8.1)	46 (10.1)	0.63
Alcoholism	27 (4.7)	5 (4.1)	22 (4.8)	0.91
Results of additional examinations				
Ultrasound Doppler of carotid arteries:				
Carotid artery disease (any plaque), n (%)	539/569 (94.7)	116/119 (97.5)	423/450 (94)	0.20
Carotid artery disease (plaque > 70%), n (%)	55/569 (9.7)	9 /119 (7.5)	47/450 (10.4)	0.44
Echocardiography:				
LVEF, %	55.5 (31.8)	55.4 (28.3)	55.7 (31.8)	0.92
LVEF < 50%, n (%)	20 (3.4)	5 (4.1)	15 (3.3)	0.89
LA [mm]	38.9 (16.7)	39.9 (9.9)	39 (18.4)	0.47
LA > 40 mm, n (%)	43 (7.4)	13 (10.6)	39 (8.6)	0.06
Laboratory tests:				
HGB [g/dl]	14.1 (13.2)	13.9 (5.9)	14.1 (8.8)	0.25
GFR [ml/min]	61.3 (44.2)	61.6 (9.9)	61.3 (6.1)	0.89
GFR < 60 ml/min, n (%)	286 (49.4)	63 (51.2)	223 (48.9)	0.72
Stroke severity				
NIHSS score at admission (mean ± SD)	3.5 (±3.9)	7.2 (±6.1)	3.7 (±4.4)	< 0.001

Continuous and ordinal variables are shown as mean (SD) unless otherwise indicated. P values are given for differences between new-AF and previous-AF groups. A p-value of < 0.05 is considered statistically significant. AF – atrial fibrillation, GFR – glomerular filtration rate, HGB – hemoglobin, LA – left atrium, LVEF – left ventricular ejection fraction, NIHSS – National Institutes of Health Stroke Scale, TIA – transient ischemic attack.

**Table II.** Risk of thromboembolism of the study group

Characteristic	All patients with AF n = 579	New-AF group n = 123	Previous-AF group n = 456	P-value
CHADS <sub>2</sub> during hospitalization	4.1 (1.4)	3.8 (1.03)	4.1 (2.1)	0.005
CHADS <sub>2</sub> before hospitalization	2.5 (1.4)	2.1 (0.7)	2.6 (2.1)	< 0.001
CHADS <sub>2</sub> before hospitalization, n (%):				
CHADS <sub>2</sub> = 0	15 (2.6)	0	15 (3.3)	0.05
CHADS <sub>2</sub> = 1	108 (18.6)	41 (33.3)	67 (14.7)	< 0.001
CHADS <sub>2</sub> ≥ 2	456 (78.8)	82 (66.7)	374 (82)	< 0.001
CHA <sub>2</sub> DS <sub>2</sub> VASc during hospitalization	6.5 (2.1)	6.3 (1.5)	6.6 (2.8)	0.08
CHA <sub>2</sub> DS <sub>2</sub> VASc before hospitalization	4.9 (2.1)	4.6 (0.7)	5.1 (2.8)	0.001
CHA <sub>2</sub> DS <sub>2</sub> VASc before hospitalization, n (%):				
CHA <sub>2</sub> DS <sub>2</sub> VASc = 0	1 (0.2)	0	1 (0.2)	1
CHA <sub>2</sub> DS <sub>2</sub> VASc = 1	10 (1.7)	3 (2.4)	7 (1.6)	0.45
CHA <sub>2</sub> DS <sub>2</sub> VASc ≥ 2	568 (98.1)	120 (97.6)	448 (98.2)	0.71
CHA <sub>2</sub> DS <sub>2</sub> VASc ≥ 3	544 (93.6)	114 (92.7)	430 (94.3)	0.65
CHA <sub>2</sub> DS <sub>2</sub> VASc ≥ 4	479 (82.7)	95 (77.2)	384 (84.2)	0.09
CHA <sub>2</sub> DS <sub>2</sub> VASc ≥ 5	366 (80.3)	62 (50.4)	304 (66.7)	0.001

Continuous and ordinal variables are shown as mean (SD) unless otherwise indicated. P-values are given for differences between new-AF and previous-AF groups. A p-value of < 0.05 is considered statistically significant. AF – atrial fibrillation.

sion proved to be the most significant indicator of death during hospitalization. In the previous-AF group, the most significant risk factors for mortality included the NIHSS score at admission and multiple ischemic foci (Table III).


#### Multivariate analyses of predictors of death at hospitalization in the new-AF group and the previous-AF group

Table IV shows predisposing factors of mortality identified in multivariate analyses. It was observed that the NIHSS score at admission in the new-AF group was associated with higher mortality, while in the previous-AF group the NIHSS score at admission and multiple ischemic foci presented higher risk for in-hospital mortality.

#### Discussion

Atrial fibrillation is a common cause of thromboembolic incidents, including stroke. Arrhythmia is often asymptomatic, but lack of symptoms does not reduce the risk of stroke, even when compared to symptomatic AF [15–17]. In patients known to have AF, the risk of stroke can be minimized with anticoagulation therapy [7, 18, 19]. Thus, in asymptomatic patients not undergoing anticoagulation therapy, the stroke risk is potentially higher than in symptomatic individuals receiving treatment for AF.

In this study, we determined that among acute ischemic stroke patients with AF, the population with newly diagnosed AF was 21%. Clinical study of the incidence of AF *de novo* in stroke patients



The distribution of CHA<sub>2</sub>DS<sub>2</sub>-VASc score is significantly different between the groups ( $p = 0.032$ )

**Figure 2.** Patients in the study group at the time of ischemic stroke according to CHA<sub>2</sub>DS<sub>2</sub>-VASc score. CHA<sub>2</sub>DS<sub>2</sub>-VASc score is calculated at the time of the ischemic event and scoring does not include the current event

is limited. The Jaakkola *et al.* study of a group of 3,623 patients showed that AF *de novo* was observed in 21.9% of stroke patients and in 16.4% of TIA patients [18]. A similar rate was noted in other studies, in which AF was diagnosed in 22.2–22.6% of stroke patients [19, 20]. Borowsky *et al.* reported AF *de novo* in 18% of 856 patients [21].

In this study on a population of patients with an ischemic stroke, most of them (70.5%) were over 74 years of age. Their collective pre-stroke CHA<sub>2</sub>DS<sub>2</sub>VASc mean score was 4.9 points and CHADS<sub>2</sub> was 2.5 points.

The studied group consisted mainly of elderly individuals with high risk of thromboembolic events. In a separate study, Borowsky *et al.* reported CHA<sub>2</sub>DS<sub>2</sub>-

**Table III.** Univariate analyses of predictors of death at hospitalization in both groups

Predictors of death during hospitalization	New-AF group (n = 123)		Previous-AF group (n = 456)	
	Odds ratio (95% CI)	P-value	Odds ratio (95% CI)	P-value
Demographics:				
Age (per 1 year)	0.94 (0.88, 1)	0.04	0.93 (0.88, 0.97)	0.001
Age > 79 years	0.06 (0.01, 0.48)	0.008	0.06 (0.01, 0.44)	0.006
Female	0.47 (0.15, 1.5)	0.20	0.47 (0.17, 1.29)	0.14
Medical history:				
Hypertension	0.93 (0.19, 4.55)	0.93	0.95 (0.33, 2.8)	0.93
Heart failure	0.81 (0.23, 2.82)	0.74	3.03 (0.39, 23.31)	0.29
Diabetes mellitus	0.53 (0.11, 2.55)	0.43	0.57 (0.16, 2.03)	0.39
Previous thromboembolism	0.17 (0.01, 2.99)	0.23	1.82 (0.65, 5.13)	0.26
Previous stroke	0.2 (0.01, 3.48)	0.27	2.21 (0.78, 6.23)	0.13
Previous TIA	0.55 (0.02, 17.57)	0.74	1.56 (0.2, 12.49)	0.67
Coronary artery disease	0.5 (0.13, 1.94)	0.32	1.61 (0.57, 4.5)	0.37
CHADS <sub>2</sub> before hospitalization (per one point)	0.63 (0.36, 1.1)	0.11	0.8 (0.53, 1.2)	0.28
CHA <sub>2</sub> DS <sub>2</sub> VASc before hospitalization (per one point)	0.66 (0.45, 0.96)	0.03	0.75 (0.56, 1.02)	0.07
CHA <sub>2</sub> DS <sub>2</sub> VASc before hospitalization ≥ 2	0.45 (0.05, 4.39)	0.49	0.24 (0.03, 2.1)	0.19
CHA <sub>2</sub> DS <sub>2</sub> VASc before hospitalization ≥ 5	0.52 (0.16, 1.69)	0.28	0.29 (0.1, 0.8)	0.02
CHADS <sub>2</sub> during hospitalization (per 1 case)	0.7 (0.39, 1.27)	0.25	0.51 (0.29, 0.87)	0.01
CHA <sub>2</sub> DS <sub>2</sub> VASc during hospitalization (per 1 case)	0.7 (0.48, 1.02)	0.06	0.61 (0.43, 0.85)	0.004
Bleeding during hospitalization	0.36 (0.02, 7.9)	0.52	2.19 (0.27, 17.85)	0.46
Results of additional examinations				
Ultrasound Doppler of carotid arteries:				
Carotid artery disease (any plaque)	1.86 (0.06, 56.82)	0.72	3.22 (0.16, 63.08)	0.44
Carotid artery disease (plaque > 70%)	4.2 (0.73, 24.15)	0.11	1.75 (0.37, 8.22)	0.48
Echocardiography:				
LVEF < 50%	0.36 (0.02, 7.9)	0.52	0.37 (0.02, 8.06)	0.53
LA > 40 mm	0.18 (0.01, 3.22)	0.25	0.2 (0.01, 3.39)	0.26
GFR < 60 ml/min	1.6 (0.49, 5.2)	0.43	1.36 (0.5, 3.71)	0.55
Laboratory tests:				
HGB < 12 g/dl	3.83 (0.87, 16.76)	0.08	2.67 (0.73, 9.82)	0.13
Other:				
Hemorrhagic transformation of ischemic stroke	0.36 (0.02, 7.9)	0.52	2.38 (0.29, 19.49)	0.42
Multiple ischemic foci	18.21 (0.6, 555.68)	0.096	12.43 (2.22, 69.69)	0.004
NIHSS during admission	1.36 (1.19, 1.56)	< 0.001	1.32 (1.2, 1.44)	< 0.001
Alteplase	0.16 (0.01, 2.79)	0.21	0.25 (0.01, 4.48)	0.34

CI – confidence interval, NIHSS – National Institutes of Health Stroke Scale, AF – atrial fibrillation, GFR – glomerular filtration rate, HGB – hemoglobin, LA – left atrium, LVEF – left ventricular ejection fraction, TIA – transient ischemic attack.

VASc ≥ 2 points in 89% of patients with stroke and AF. In this study, the new-AF group did not differ from the previous-AF group in age and sex. However, previous-AF group members were more likely than new-AF group members to suffer from hypertension, coronary artery disease, and heart failure, and have a history of thromboembolism. Mean pre-stroke

CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>VASc scores were higher in the previous-AF than in the new-AF group.

Interestingly, when CHA<sub>2</sub>DS<sub>2</sub>VASc scores reached 5 points and higher, the higher scores led to statistically significant differences in the outcome. Therefore, in the previous-AF group, very high stroke risk was more prevalent than in the new-AF group.



**Table IV.** Multivariate analyses of predictors of death at hospitalization in both groups

Predictors of death during hospitalization	New-AF group (n = 123)		Previous-AF group (n = 456)	
	Odds ratio (95%CI)	P-value	Odds ratio (95%CI)	P-value
Age (per 1 year)	1.04 (0.92, 1.18)	0.55	0.96 (0.88, 1.05)	0.34
CHA <sub>2</sub> DS <sub>2</sub> VASc before hospitalization (per one point)	0.79 (0.43, 1.46)	0.46	0.77 (0.4, 1.49)	0.44
Hemorrhagic transformation of ischemic stroke	0.23 (0.01, 10.3)	0.45	0.98 (0.02, 46.68)	0.99
Multiple ischemic foci	1.07 (0.01, 98.64)	0.98	97.13 (6.65, 1418.87)	0.001
Previous stroke	0.22 (0.01, 9.28)	0.42	2.37 (0.26, 21.84)	0.45
NIHSS during admission	1.38 (1.19, 1.6)	< 0.001	1.31 (1.19, 1.46)	< 0.001
HGB < 12 g/dl	1.86 (0.17, 20.32)	0.61	1.36 (0.18, 10.12)	0.77

AF – atrial fibrillation, NIHSS – National Institutes of Health Stroke Scale, HGB – hemoglobin.

However, a higher mean NIHSS score was noted in the new-AF group than in the previous-AF group. During their hospital stay, 10.6% of patients in the new-AF group and 3.5% in the previous-AF group died, representing an overall total of 5% of patients with coexisting stroke and AF.

Our findings are in accordance with reports by other authors. In a group of 4278 ischemic stroke patients, AF was associated with increased in-hospital mortality in women but not in men compared with patients without AF [22]. Based on the Austrian Stroke Registry, the in-hospital mortality due to ischemic stroke with AF was 25%, while it was 14% for patients without arrhythmia [23]. In the Austrian group of 25,319 patients with an ischemic stroke and AF, the in-hospital mortality rate was 14.1%, while it was 6.2% when AF was not present [24]. Borowsky *et al.* reported even higher mortality of 15% in patients newly diagnosed with AF [21]. In our study the new AF was probably not new, but newly detected. Most likely, it was a non-paroxysmal AF, which is more often asymptomatic and less frequently detected.

Deguchi *et al.* suggested that the type of atrial fibrillation affects stroke severity and clinical outcomes following cerebral infarction. In a study of 9293 patients with cardioembolic stroke and AF, those with persistent AF had significantly higher stroke severity on admission than those with paroxysmal AF, and persistent AF was a factor contributing to the in-hospital mortality [25].

In this study, we identified predisposing risk factors of in-hospital mortality in patients with stroke and atrial fibrillation *de novo* as well as in patients with a previous diagnosis of this arrhythmia. In the previous-AF group, we found in univariate analysis that multiple ischemic foci and high NIHSS score were associated with higher mortality. Interestingly, age and a pre-stroke CHA<sub>2</sub>DS<sub>2</sub>-VASc score > 5 were associated with lower risk.

In the univariate analysis of the new-AF group, a high NIHSS score at admission was associated

with higher mortality, while high stroke risk resulted in lower mortality. In multivariate analysis, we confirmed that a high NIHSS score at admission was a risk factor of high mortality in the new-AF group, while a high NIHSS score at admission and multiple ischemic foci were risk factors of in-hospital mortality in the previous-AF group. In the multivariate analysis, it was not confirmed that high stroke risk expressed on the CHA<sub>2</sub>DS<sub>2</sub>VASc scale had an impact on the in-hospital mortality of either the new-AF group or the previous-AF group.

Most published research on the subject at this time indicates that a high stroke risk is a poor prognostic factor for a long-term follow-up of stroke patients [26, 27]. It is possible that a prolonged observation affected the results. In this study, we found that the most predictive factors of in-hospital mortality in stroke patients with AF included neurological status manifested by a NIHSS score at admission as well as multiple ischemic foci. These observations have been corroborated by other authors [27].

The ESC guidelines recommend regular assessment of rhythm in screening for occult AF in all patients over the age of 65 [14]. This study shows that patients with stroke and newly diagnosed AF have poor prognosis regardless of age and comorbidities. Therefore, it is justified to screen for occult AF in young patients without concurrent medical conditions since asymptomatic AF significantly increases the risk of stroke [15].

In the Cryptogenic Stroke and Underlying Atrial Fibrillation (CRYSTAL-AF) study conducted on patients with cryptogenic stroke, those receiving standard care were compared with those fitted with an implantable loop recorder. In follow-up research conducted 6 months after enrollment in the study, 8.9% were diagnosed with AF for the first time. At 12-months follow-up, 12.4% were newly diagnosed with AF [28].

In the Asymptomatic Stroke and Atrial Fibrillation Evaluation in Pacemaker Patients (ASSERT)

trial, no definite temporal relationship was found between short asymptomatic episodes of AF and stroke [29]. The role of AF in the pathogenesis of thromboembolism is well established; however, other mechanisms can be present in patients with arrhythmia that leads to stroke.

There are several limitations of our study. As is the case for all retrospective studies, there exist potential unidentified confounders. We could not adjust for an individual-level socioeconomic status, form of AF and burden of AF in the study group. Our data source could not ascertain the date of thromboembolic prevention and other treatment before hospitalization. Data on anticoagulant and antiplatelet treatment in a significant number of participants were unknown and could not be obtained due to the retrospective nature of the study. Another limitation of our study is that data on some of the variables were not available for all of the patients (i.e. ultrasound doppler of carotid arteries, echocardiography).

In conclusion, newly diagnosed AF in ischemic stroke patients significantly worsens short-term prognosis compared to patients with earlier diagnosed AF. Stroke severity on admission was found to be the most significant predisposing risk factor for the in-hospital mortality for all ischemic stroke patients with AF.

Our results emphasize the importance of detecting latent atrial fibrillation, to improve stroke outcomes through effective prevention with anticoagulation therapy.

## Funding

No external funding.

## Ethical approval

Approval number: 3/2021-VIII.

## Conflict of interest

The authors declare no conflict of interest.

## References

- Chen LY, Shen WK. Epidemiology of atrial fibrillation: a current perspective. *Heart Rhythm* 2007; 4: S1-6.
- Boysen G, Nyboe J, Appleyard M, et al. Stroke incidence and risk factors for stroke in Copenhagen, Denmark. *Stroke* 1988; 19: 1345-53.
- Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. *J Am Coll Cardiol* 1994; 23: 961-9.
- Petersen P, Kastrup J, Videbaek R, Boysen G. Cerebral blood flow before and after cardioversion of atrial fibrillation. *J Cereb Blood Flow Metab* 1989; 9: 422-5.
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 1991; 22: 983-8.
- Staszewski J, Wąsek W. [Secondary prevention of cardiogenic stroke in nonvalvular atrial fibrillation]. *Neurologia po Dyplomie* 2016; 11: 21-35.
- Alberts M, Chen YW, Lin JH, Kogan E, Twyman K, Milentijevic D. Risks of stroke and mortality in atrial fibrillation patients treated with rivaroxaban and warfarin. *Stroke* 2020; 51: 549-55.
- Wańkowicz P, Staszewski J, Dębiec A, Nowakowska-Kotas M, Szylińska A, Rotter I. Ischemic stroke risk factors in patients with atrial fibrillation treated with new oral anticoagulants. *J Clin Med* 2021; 10: 1223.
- Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complication in chronic atrial fibrillation. The Copenhagen AFASAK Study. *Lancet* 1989; 1: 175-9.
- Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. *J Am Coll Cardiol* 1991; 18: 349-55.
- Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. *Stroke* 2005; 36: 1115-9.
- Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: the Framingham study. *Stroke* 1996; 27: 1760-4.
- Pastuszek Ż, Koźniewska E, Stępień A, Piusińska-Macoch A, Czernicki Z, Koszewski W. Importance rating of risk factors of ischemic stroke in patients over 85 years old in the polish population. *Neurol Neurochir Pol* 2018; 52: 88-93.
- Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). *Europace* 2010; 12: 1360-420.
- Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. *N Engl J Med* 2012; 366: 120-9.
- Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. *Circulation* 2013; 127: 930-7.
- Roche F, Gaspoz JM, Da Costa A, et al. Frequent and prolonged asymptomatic episodes of paroxysmal atrial fibrillation revealed by automatic long-term event recorders in patients with a negative 24-Hour Holter. *Pacing Clin Electrophysiol* 2002; 25: 1587-93.
- Jaakkola J, Mustonen P, Kiviniemi T, et al. Stroke as the first manifestation of atrial fibrillation. *PLoS One* 2016; 11: e0168010.
- Lin HJ, Wolf PA, Benjamin EJ, Belanger AJ, D'Agostino RB. Newly diagnosed atrial fibrillation and acute stroke. The Framingham study. *Stroke* 1995; 26: 1527-30.
- Vingerhoets F, Bogousslavsky J, Regli F, Van Melle G. Atrial fibrillation after acute stroke. *Stroke* 1993; 24: 26-30.
- Borowsky LH, Regan S, Chang Y, Ayres A, Greenberg SM, Singer DE. First diagnosed of atrial fibrillation at the time of stroke. *Cerebrovasc Dis* 2017; 43: 192-9.
- Ong CT, Wong YS, Sung SF, et al. Sex-related differences in the risk factors for in-hospital mortality and outcomes of ischemic stroke patients in rural areas of Taiwan. *PLoS One* 2017; 12: e0185361.
- Steger C, Pratter A, Martinek-Bregel M, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke Registry. *Eur Heart J* 2004; 25: 1734-40.



24. Kongbunkiat K, Kasemsap N, Travanichakul S, Thepsuthammarat K, Tiamkao S, Sawanyawisuth K. Hospital mortality from atrial fibrillation associated with ischemic stroke: a national data report. *Int J Neurosci* 2015; 125: 924-8.
25. Deguchi I, Hayashi T, Fukuoka T, Kobayashi S, Tanahashi N; Japan Standard Stroke Registry Study Group. Features of cardioembolic stroke with persistent and paroxysmal atrial fibrillation – a study with the Japan Stroke Registry. *Eur J Neurol* 2015; 22: 1215-9.
26. Tu HT, Campbell BC, Meretoja A, et al. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation. *Cerebrovasc Dis* 2013; 36: 273-80.
27. Li S, Zhao X, Wang C, et al. Risk factors for poor outcome and mortality at 3 months after the ischemic stroke in patients with atrial fibrillation. *J Stroke Cerebrovasc Dis* 2013; 22: 419-25.
28. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med* 2014; 370: 2478-86.
29. Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. *Circulation* 2014; 129: 2094-9.